CureVac Stock Just Got Upgraded. It’s Now a Competitor in mRNA Vaccines.
Text size
CureVac stock has surged since reporting promising mRNA trial data on Jan. 6.
Jeroen Jumelet/ANP/AFP via Getty Images
…
Text size
Jeroen Jumelet/ANP/AFP via Getty Images
…